Evotec
Bernd Muehlenweg's work experience includes various senior leadership roles in the biotech and pharmaceutical industry. Bernd currently serves as the Senior Vice President of Global Business Development at Evotec, where they lead the company's efforts in areas such as cell therapy, precision medicine, oncology, immunology, and infectious diseases. Bernd is also responsible for overseeing the business development and licensing activities of Evotec's Innovate segment. Prior to joining Evotec, Muehlenweg co-founded Panoptes Pharma GmbH, a biotech company focused on developing therapies for eye diseases, which was later acquired by Eyegate Pharmaceuticals. Bernd also held the position of Chief Business Officer and served on the Executive Board of Nanobiotix, a pre-clinical biotech company. Additionally, they have experience in business development and alliance management at Wilex AG, where they played a key role in the company's growth and expansion. Muehlenweg began their career as a Group Leader at the Technical University Munich.
Bernd Muehlenweg attended the St. Galler Business School in 2006, where they studied Management. Prior to that, they pursued a Ph.D. in Oncology and Biochemistry at the Technical University of Munich from 1997 to 2000. Bernd obtained their Dipl. Chem. degree in Chemistry and Biochemistry from Bielefeld University between 1991 and 1996. In 1995, Bernd Muehlenweg also briefly studied Biophysical Chemistry at Dublin City University.
This person is not in the org chart
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.